Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04181-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Xiangqi Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Peking, Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Chi…. Hauptthemen laut MEDLINE: Immunotherapy, Biliary Tract Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To assess the incidence, clinical characteristics, and post-progression management strategy of resistance to immunotherapy–chemotherapy combination in unresectable biliary tract carcinoma (uBTC). Experimental Design Patients with uBTC from multiple centers who received immunotherapy–chemotherapy combination were retrospectively included. Baseline characteristics, treatments, pattern of progression, and posttreatment managements were recorded. The primary endpoint was post-progression survival (PPS).
Results
Out of 194 patients, 130 (67.0%) developed resistance, including 78 (40.2%) with acquired resistance (AR) and 52 (26.8%) with primary resistance (PR). Normal CA19-9 level and combining target therapy were more common in patients with AR. Patients with both AR and PR commonly experience deterioration in general condition and systemic progression. Patients with AR and PR showed no difference in patterns of progression or current post-progression management strategies. A total of 103 (79.2%) patients receiving post-resistance antitumor treatments showed improved prognosis than those receiving best supportive care, while patients with AR received additional survival benefit than those with PR. Changing immunotherapy regimen after resistance brings significant survival benefit in patients with AR (mPPS: 15.1 vs. 9.50 months, HR = 0.41), but not those with PR. Adding/switching target therapy regimens (HR = 0.39) and local regional therapies (LRT) (HR = 0.36) after resistance brings potential benefit in patients with PR.
Conclusions
Changing immunotherapy regimen is a promising strategy for overcoming AR to first-line immunotherapy–chemotherapy combination in uBTC, while adjusting targeted therapy and adding LRT may help overcome PR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Liver Surgery, Peking, Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, China. whofo1986@163.com.
- Department of General Surgery Center, Clinical Center for Liver Cancer, Beijing Youan Hospital, Capital Medical University, Beijing, China. pumchzcp@126.com.
- Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, China. zhuzy302@163.com.
- Department of Liver Surgery, Peking, Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. zhaoht@pumch.cn.
Zitieren
APA
Chen, X., Zhou, Z., Li, S., Yu, G., Feng, S., Zhou, Z., Sun, B., Wang, S., Liu, K., Li, C., Piao, M., Wang, M., Zhang, Y., Li, H., Zhu, C., Zhu, Z., & Zhao, H. (2025). Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04181-2
Vancouver
Chen X, Zhou Z, Li S, Yu G, Feng S, Zhou Z, et al. Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04181-2
BibTeX
@article{Chen2025,
author = {Chen, Xiangqi and Zhou, Zixiang and Li, Shuofeng and Yu, Guanhua and Feng, Shi and Zhou, Ze and Sun, Boyu and Wang, Shanshan and Liu, Kai and Li, Chengjie and Piao, Mingjian and Wang, Mingming and Zhang, Yihong and Li, Hu and Zhu, Chengpei and Zhu, Zhenyu and Zhao, Haitao},
title = {Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04181-2}
}
EUVIMED